WWW.REFERATCENTRAL.ORG.UA - Я ТУТ НАВЧАЮСЬ

... відкритий, безкоштовний архів рефератів, курсових, дипломних робіт

ГоловнаМедицина → Інфаркт міокарда (біохімічні маркери). - Курсова робота

Інфаркт міокарда (біохімічні маркери). - Курсова робота

W. Klein, A. Buchwald, S. Hillis et al. Comparison of Low-Molecular-Weight Heparin With Unfractionated Heparin Acutely and With Placebo for 6 Weeks in the Management of Unstable Coronary Artery Disease. Fragmin inUnstable Coronary Artery Disease Study (FRIC). Circulation 1997; 96: 61-68.
28. The FRAX. I. S. Study Group. Comparison of two treatment durations (6 days and 14 days) of low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction: FRAX. I. S. (FRAxiparine in Ischemic Syndrome). Eur Heart J 1999; 20: 1553-1562.
29. M. Cohen, C. Demers, E. Gurfinkel et al. A comparison of low-molecular-weight heрarin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447-452.
30. E. Antman, C. McCabe, E. Gurfinkel et al. Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non-Q-Wave Myocardial Infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B Trial. Circulation 1999:100: 1593-1601.
31. Antman E. M., Cohen M., Radley D. et al. Assessment of the Treatment Effect of Enoxaparin for Unstable Angina/Non-Q-Wave Myocardial Infarction. TIMI 11B-ESSENCE Meta-Analysis. Circulation 1999:100: 1602-1608.
32. FRISC II Investigators. Long-term low-molecular-mass heparin in unstable coronary artery disease: FRISC II prospective randomized multicentre study. Lancet 1999; 354: 701-707.
33. S. Husted, R. Becker, A. Kher. A Critical Review of Clinical Trials for Low-Molecular-Weight Heparin Therapy in Unstable Coronary Artery Disease. Clin Cardiol 2001; 24: 492-499.
34. FRISC II Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomized multicentre study. Lancet 1999; 354: 708-715.
35. J. Coillet, G. Montalescot, L. Lison, et al. Percutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment in Patients With Unstable Angina Pectoris. Circulation 2001; 103: 658-663.
36. M. Rabah, J. Premmereur, M. Graham et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999; 84: 1391-1395.
37. D. Kereiakes, C. Grines, E. Fry et al. Enoxaparin and abxicimab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001; 13: 272-278.
38. K. Karsch, M. Preisack, B. Baildon et al.and REDUCE trial group. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty: Results of randomized, double-blind, unfractionated heparin and and placebo-controlled, multicenter trial (REDUCE trial). JACC 1996:28: 1437-1443.
39. D. Dudek, P. Zymek, S. Bartus, et al. Prospective randomized comparison of enoxaparin versus unfractionated heparin for elective percutaneous coronary interventions among ticlopidine-pretreated patients. Eur Heart J 2000; 21: (abstr.suppl): 381.
40. J. Zidar. Low molecular weight heparins in coronary stenting. The ENTICES trial. Am J Cardiol 1998; 82: 29L-32L.
41. M. Cohen. Initial experience with the n of combination therapy with the low-molecular-weight heparin, enoxaparin, in combination with platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes. J Invasive Cardiol 2000; 12 (suppl. E): 5-9.
42. D. Kereiakes, N. Kleiman, E. Fry et al. Dalterarin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001; 141: 348-352..
43. D. Dudek, S. Bartus, P. Zymek et al. Abciximab and Enoxaparin Administration During Elective High-Risk PTCA in Patients With More Than 3 Days of Ticlopidine Pretreatment. JACC 2000; 35 (suppl A): 91.
44. R. Kiesz, P. Buszman, M. Rozek et al. Local delivery of low-molecular-weight heparin decreases restenosis rate after coronary stenting: final results of the POLONIA randomized study. Eur Heart J 2000; 21 (abstr.suppl.): 366.
45. N. Meneveau, J-P Bassand, G. Grollier et al. Local delivery of nadroparin for the prevention of neointimal hyperplasia following stent implantation: final results of the IMPRESS trial. Eur Heart J 2000; 21 (abstr.suppl.): 366.
46. S. Clark, N. Vitale, J. Zacharias, J. Forty. Effect of low molecular weight heparin (fragmin) on bleeding after surgery. Ann Thorac Surg 2000; 69: 762-764.
47. A. Camm. Atrial fibrillation: is there a role for low-molecular-weight heparin? Clin Cardiol 2001; 24 (suppl. 3): 115-119.
48. A. Roijer, J. Eskilsson, B. Olsson. Transoesophageal echocardiographyguided cardioversion of atrial fibrillation or flutter: selection of a low-risk group for immediate cardioversion. Eur Heart J 2000; 21: 837-847.
49. H. Bechtold, H. Sawitzki, D. Guzenhauser, D. Janssen. Anticoagulation with low-molecular-weight heparin dalteparin in atrial fibrillation. Eur Heart J 2000; 21 (abstr.suppl.): 8.
Главная страница С о д е р ж а н и е Редколлегия Поиск на РМЖ Расширенный поиск - -"
Адрес эл. почты редакции: postmaster@wolga.msk.ru
W e bMaster
© Русский Медицинский Журнал 2000 год. http://www. RMJ. ru тел. (095) 284 - 7627
1. ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). JACC 2000; 36: 970-1062.
2. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart Journal 2000; 21: 1406-1432.
3. Myocardial Infarction Redefined ? A Consensus Document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. The Joint European Society of Cardiology/American College of Cardiology Committee. Eur Heart J 2000; 21: 1502-13/JACC 2000; 36: 959-69. 4. ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). JACC 1999; 33: 2092-197.
5. Явелов И.С. Антитромбины в лечении острого коронарного синдрома без подъема сегмента ST: современное состояние проблемы. Консилиум 2000; 2 (11): 454-60.
6. Richard R.C., Spencer F.A., Li Y., Ball S.P., Ma Y., Hurley T., Hebert J. Thrombin Generation After the Abrupt Cessation of Intravenous Unfractionated Heparin Among Patients With Acute Coronary Syndromes. JACC 1999; 34: 1020-7.
{C}
Loading...

 
 

Цікаве